查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1881346

全球蛋白质疗法市场（依产品、应用和地区划分）－市场规模、产业趋势、机会分析及预测（2025-2033 年）

Global Protein Therapeutics Market: By Product, Applications, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

目前，该市场正经历强劲且充满活力的成长，预计到 2024 年市场规模将达到 2,298 亿美元。这一成长趋势预计将在未来几年持续强劲，预计到 2033 年，市场规模将成长近一倍，达到 4,268 亿美元。这一成长意味着 2025 年至 2033 年预测期内的复合年增长率 (CAGR) 为 7.12%，反映了各个治疗领域持续且加速成长的需求。

推动这令人瞩目的成长因素有很多。其中一个关键推动因素是神经病学领域一系列突破性监管审批的出台，这些审批促成了针对复杂神经系统疾病的创新生物疗法的问世。这些新疗法满足了以往未被满足的医疗需求，并为患有慢性且往往致残性疾病的患者带来了希望。同时，GLP-1受体激动剂的处方量显着增长，尤其是在糖尿病和肥胖等代谢性疾病的治疗方面。

市场趋势

蛋白质疗法市场的竞争策略围绕着精准标靶疗法（例如单株抗体 (mAb)）的开发、研发方面的大量投资以及获得监管支持以加快新生物製剂的审批。各公司越来越关注精准医疗方法，以实现针对特定疾病机制的个人化治疗，而单株抗体由于其靶向分子通路的能力，正是这一趋势的体现。

这一趋势的一个显着例子是，AbraBio与武田药品工业株式会社于2025年10月达成一项多年研究合作，旨在利用人工智慧推进蛋白质疗法的设计。此次合作标誌着人工智慧和生物技术的融合日益加深，各公司正利用运算工具加速新型蛋白质药物的发现和优化。作为协议的一部分，Avrabio 将获得一笔预付款和持续的研究经费，并有可能获得超过 10 亿美元的成功付款，这凸显了尖端蛋白质疗法开发的高风险和财务投入。

为了进一步说明该领域蓬勃发展的融资环境，2025 年 6 月，专注于体内蛋白质疗法生产的先锋生物技术公司 Signify Bio 宣布完成了超额认购的 1500 万美元首轮融资。本轮融资由 Actium Group 领投，其他知名投资者包括盖兹基金会战略投资基金、丹纳赫创投公司（丹纳赫集团子公司）、礼来公司以及美国癌症协会 (ACS) 的创投机构 BrightEdge。

核心成长驱动因子

细胞和基因疗法 (CGT) 的快速发展正在更广泛的蛋白质疗法市场中创造对高度专业化蛋白质的巨大新需求。这些先进疗法高度依赖蛋白质成分，特别是作为将遗传物质递送到患者细胞的载体。到 2024 年初，已有超过 420 种利用蛋白质载体的基因疗法进入临床试验阶段，这表明蛋白质在这些创新疗法的开发和功能中发挥着至关重要的作用。

新兴机会

血浆蛋白疗法市场预计将迎来显着成长，主要受两大因素驱动：原材料供应链的不断扩大以及对先进疗法日益增长的临床需求。推动这一成长的关键因素是血浆采集网路的快速扩张，这对于满足全球患者不断增长的治疗需求至关重要。光是在美国，CSL Plasma 和 Octapharma 等大型血浆采集公司就大幅扩展业务。例如，CSL Plasma 已将其采集中心扩展到 300 多个地点，反映出增加血浆供应对于支持血浆衍生药物生产的重要性。

优化障碍

蛋白质疗法的开发和生产成本高昂，是可能阻碍市场成长的一大障碍。开发这些先进的生物製剂是一个复杂的过程，涉及广泛的研究、临床试验和严格的监管要求，所有这些都需要大量的资金投入。生产阶段也增加了额外的成本，因为生产蛋白质类药物需要专门的设施、先进的技术和严格的品质控制措施，以确保安全性和有效性。这些成本的累积效应会导致最终产品价格高昂，从而限制患者的获得。

目录

第一章：研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第二章：研究方法

  • 质性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 依地区划分的一手调查受访者组成
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章：摘要整理：全球蛋白质治疗市场

第四章：全球蛋白质治疗市场概述

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 製程类型
  • 行业展望
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场动态与趋势
    • 成长推动因素
    • 阻碍因素
    • 挑战
    • 主要趋势
  • 市场成长与展望
    • 市场收入估计与预测（2020-2033）
    • 价格趋势分析
  • 竞争格局概览
    • 市场集中度
    • 公司竞争占有率分析（价值，2024 年）
    • 竞争格局分析与基准分析
  • 实务洞察（分析师建议）

第五章 全球蛋白质疗法市场分析：依产品分类

  • 主要洞察
  • 市场规模及预测（2020-2033 年）
    • 单株抗体
    • 胰岛素
    • 融合蛋白
    • 促红血球生成素
    • 干扰素
    • 人类生长激素
    • 促卵泡激素

第六章：全球蛋白质疗法市场分析：依应用领域划分

  • 主要见解
  • 市场规模及预测（2020-2033）
    • 代谢性疾病
    • 免疫系统疾病
    • 血液系统疾病
    • 癌症
    • 内分泌疾病
    • 遗传性疾病

第七章：全球蛋白质疗法市场区域分析

  • 主要见解
  • 市场规模及预测（2020-2033）
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美

第八章：北美蛋白质疗法市场分析

第九章：欧洲蛋白质疗法市场分析治疗药物市场分析

第十章：亚太地区蛋白质治疗药物市场分析

第十一章：中东与非洲蛋白质治疗药物市场分析

第十二章：南美洲蛋白质治疗药物市场分析

第十三章：公司简介

  • 拜耳公司
  • 百时美施贵宝公司
  • 第一三共株式会社
  • 雅培公司
  • 赛诺菲公司
  • 赛默飞世尔科技公司
  • 健赞公司
  • 艾伯维公司
  • Leadiant Biosciences公司
  • 武田药品工业株式会社
  • 其他主要企业

第十四章附录

简介目录
Product Code: AA11251565

The market is currently experiencing dynamic and robust growth, with its valuation reaching US$ 229.8 billion in 2024. This upward trajectory is expected to continue strongly over the coming years, with projections indicating that the market will nearly double to an estimated valuation of US$ 426.8 billion by 2033. This expansion corresponds to a compound annual growth rate (CAGR) of 7.12% during the forecast period from 2025 to 2033, reflecting sustained and accelerating demand across various therapeutic areas.

Several key factors are driving this impressive growth. One of the primary catalysts is the groundbreaking wave of regulatory approvals in the field of neurology, which has introduced innovative biologic therapies targeting complex neurological conditions. These new treatments are addressing previously unmet medical needs, offering hope for patients with chronic and often debilitating diseases. In parallel, there has been a significant surge in prescriptions for GLP-1 agonists, particularly for metabolic disorders such as diabetes and obesity.

Noteworthy Market Developments

Competitive strategies within the protein therapeutics market are centered around the development of highly targeted therapies such as monoclonal antibodies (mAbs), substantial investments in research and development (R&D), and securing regulatory support to expedite the approval of new biologics. Companies are increasingly focusing on precision medicine approaches that enable treatments tailored to specific disease mechanisms, with monoclonal antibodies exemplifying this trend due to their ability to target molecular pathways.

A notable example of this dynamic occurred in October 2025 when abla Bio entered into a multi-year research collaboration with Takeda aimed at advancing the AI-driven design of protein therapeutics. This partnership illustrates the growing intersection between artificial intelligence and biotechnology, as companies leverage computational tools to accelerate the discovery and optimization of novel protein drugs. As part of the agreement, abla Bio received an upfront payment and ongoing research funding, with the potential to earn success-based payments exceeding $1 billion, underscoring the high stakes and financial commitment involved in cutting-edge protein therapeutics development.

Further highlighting the financial vitality of the sector, in June 2025, Signify Bio, a pioneering biotechnology company focused on harnessing the human body for in situ production of protein therapeutics, announced an oversubscribed $15 million initial financing round. This funding round was led by Actium Group and featured participation from prominent investors such as the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC (a subsidiary of Danaher Corporation), Eli Lilly and Company, and BrightEdge, the venture capital arm of the American Cancer Society (ACS).

Core Growth Drivers

The rapid expansion of cell and gene therapies (CGT) is creating a substantial new demand for highly specialized proteins within the broader protein therapeutics market. These advanced therapies rely heavily on protein-based components, particularly in the form of vectors used to deliver genetic material into patients' cells. By early 2024, there were over 420 gene therapies in clinical trials that utilize protein-based vectors, illustrating the critical role proteins play in the development and function of these innovative treatments.

Emerging Opportunity Trends

The future of the plasma protein therapeutics market is marked by significant growth driven by both an expanding supply chain for raw materials and a rising clinical demand for advanced therapies. A critical factor supporting this growth is the rapid expansion of plasma collection networks, which are essential to meet the increasing therapeutic needs of patients worldwide. In the United States alone, major plasma collectors such as CSL Plasma and Octapharma are scaling their operations significantly. CSL Plasma, for example, has expanded its network to more than 300 collection centers, reflecting the importance of increasing plasma availability to support the production of plasma-derived medicines.

Barriers to Optimization

The high cost associated with the development and manufacturing of protein therapeutics presents a significant barrier that may impede market growth. Developing these advanced biologic drugs involves complex processes, including extensive research, clinical trials, and stringent regulatory requirements, all of which contribute to substantial financial investments. These costs are further amplified during manufacturing, as producing protein-based therapies requires specialized facilities, sophisticated technology, and strict quality control measures to ensure safety and efficacy. The cumulative effect of these expenses often results in high prices for end products, which can limit patient accessibility.

Detailed Market Segmentation

By Product Type, the monoclonal antibodies segment holds a dominant position within the protein therapeutics market, commanding an impressive 51% share that reflects a fundamental shift toward precision medicine. This segment's prominence underscores how monoclonal antibodies have become essential tools for targeting specific disease mechanisms with high accuracy, offering tailored treatments that improve patient outcomes across a range of conditions. Their growing importance is evident in the regulatory landscape, where in 2024, monoclonal antibodies accounted for 13 out of the 16 new biologics approved by the U.S. Food and Drug Administration (FDA).

By Application, the metabolic disorders segment commands an impressive 33% share of the protein therapeutics market, a dominance that directly stems from the global epidemic of diabetes and obesity. These chronic illnesses affect hundreds of millions of people worldwide, creating an urgent need for effective treatments. Protein-based drugs have emerged as vital tools in managing these conditions, offering targeted approaches that help control disease progression and improve patient outcomes. Their growing importance is reflected in the substantial volume of prescriptions written over recent years, underscoring both patient demand and clinical reliance on these therapies.

Segment Breakdown

By Product

  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone

By Applications

  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America firmly holds a commanding position in the protein therapeutics market, accounting for over 42% of the global market share. This leadership is rooted in a combination of cutting-edge research capabilities and a well-organized administrative framework that supports innovation and regulatory efficiency. The region's stronghold is further reinforced by advancements in regulatory processes that streamline the development and approval of protein-based therapies.
  • North America's innovation ecosystem is vibrant and prolific, with an overwhelming number of early-stage developments in protein therapeutics underway. The U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) oversees thousands of ongoing Investigational New Drug (IND) programs focused on biologics, reflecting the depth and breadth of research activity in the region. This robust pipeline highlights the continuous efforts to discover and develop novel protein-based treatments, addressing a wide range of medical conditions.

Leading Market Participants

  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company
  • Abbott
  • Sanofi
  • Thermo Fisher Scientific Inc.
  • Genzyme Corporation
  • AbbVie Inc.
  • Leadiant Biosciences
  • Takeda Pharmaceutical Company Limited
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1 Research Objective
  • 1.2 Product Overview
  • 1.3 Market Segmentation

Chapter 2. Research Methodology

  • 2.1 Qualitative Research
    • 2.1.1 Primary & Secondary Sources
  • 2.2 Quantitative Research
    • 2.2.1 Primary & Secondary Sources
  • 2.3 Breakdown of Primary Research Respondents, By Region
  • 2.4 Assumption for the Study
  • 2.5 Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Protein Therapeutics Market

Chapter 4. Global Protein Therapeutics Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. Process Type
  • 4.2. Industry Outlook
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Market Growth and Outlook
    • 4.6.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2033
    • 4.6.2. Price Trend Analysis
  • 4.7. Competition Dashboard
    • 4.7.1. Market Concentration Rate
    • 4.7.2. Company Market Share Analysis (Value %), 2024
    • 4.7.3. Competitor Mapping & Benchmarking
  • 4.8. Actionable Insights (Analyst Recommendation's)

Chapter 5. Global Protein Therapeutics Market Analysis, By Product

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 5.2.1. Monoclonal Antibodies
    • 5.2.2. Insulin
    • 5.2.3. Fusion Protein
    • 5.2.4. Erythropoietin
    • 5.2.5. Interferon
    • 5.2.6. Human Growth Hormone
    • 5.2.7. Follicle Stimulating Hormone

Chapter 6. Global Protein Therapeutics Market Analysis, By Applications

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 6.2.1. Metabolic Disorders
    • 6.2.2. Immunologic Disorders
    • 6.2.3. Hematological Disorders
    • 6.2.4. Cancer
    • 6.2.5. Hormonal Disorders
    • 6.2.6. Genetic Disorders

Chapter 7. Global Protein Therapeutics Market Analysis, By Region

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 7.2.1. North America
      • 7.2.1.1. The U.S.
      • 7.2.1.2. Canada
      • 7.2.1.3. Mexico
    • 7.2.2. Europe
      • 7.2.2.1. Western Europe
        • 7.2.2.1.1. The UK
        • 7.2.2.1.2. Germany
        • 7.2.2.1.3. France
        • 7.2.2.1.4. Italy
        • 7.2.2.1.5. Spain
        • 7.2.2.1.6. Rest of Western Europe
      • 7.2.2.2. Eastern Europe
        • 7.2.2.2.1. Poland
        • 7.2.2.2.2. Russia
        • 7.2.2.2.3. Rest of Eastern Europe
    • 7.2.3. Asia Pacific
      • 7.2.3.1. China
      • 7.2.3.2. India
      • 7.2.3.3. Japan
      • 7.2.3.4. South Korea
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.6. ASEAN
      • 7.2.3.7. Rest of Asia Pacific
    • 7.2.4. Middle East & Africa
      • 7.2.4.1. UAE
      • 7.2.4.2. Saudi Arabia
      • 7.2.4.3. South Africa
      • 7.2.4.4. Rest of MEA
    • 7.2.5. South America
      • 7.2.5.1. Argentina
      • 7.2.5.2. Brazil
      • 7.2.5.3. Rest of South America

Chapter 8. North America Protein Therapeutics Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 8.2.1. By Product
    • 8.2.2. By Applications
    • 8.2.3. By Country

Chapter 9. Europe Protein Therapeutics Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 9.2.1. By Product
    • 9.2.2. By Applications
    • 9.2.3. By Country

Chapter 10. Asia Pacific Protein Therapeutics Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 10.2.1. By Product
    • 10.2.2. By Applications
    • 10.2.3. By Country

Chapter 11. Middle East and Africa Protein Therapeutics Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 11.2.1. By Product
    • 11.2.2. By Applications
    • 11.2.3. By Country

Chapter 12. South America Protein Therapeutics Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 12.2.1. By Product
    • 12.2.2. By Applications
    • 12.2.3. By Country

Chapter 13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 13.1. Bayer AG
  • 13.2. Bristol-Myers Squibb
  • 13.3. Daiichi Sankyo Company
  • 13.4. Abbott
  • 13.5. Sanofi
  • 13.6. Thermo Fisher Scientific Inc.
  • 13.7. Genzyme Corporation
  • 13.8. AbbVie Inc.
  • 13.9. Leadiant Biosciences
  • 13.10. Takeda Pharmaceutical Company Limited
  • 13.11. Other Prominent Players

Chapter 14. Annexure

  • 14.1. List of Secondary Sources
  • 14.2. Key Country Markets- Macro Economic Outlook/Indicators